Table 2.
Change in HbA1c from baseline at endpoint in subgroups (FAS).
| Vildagliptin 50 mg bid (N = 188) |
Voglibose 0.2 mg tid (N = 192) |
|||||
|---|---|---|---|---|---|---|
| Subgroup category | n* | Baseline mean | Change from baseline mean (s.e.) | n* | Baseline mean | Change from baseline mean (s.e.) |
| Baseline HbA1c (%) | ||||||
| ≤7 | 65 | 6.73 | −0.56 (0.043) | 65 | 6.71 | −0.27 (0.060) |
| >7, ≤8 | 71 | 7.42 | −0.95 (0.049) | 72 | 7.49 | −0.37 (0.064) |
| >8 | 52 | 8.73 | −1.35 (0.094) | 55 | 8.85 | −0.49 (0.112) |
| BMI at baseline | ||||||
| <25 kg/m2 | 107 | 7.49 | −0.96 (0.056) | 106 | 7.59 | −0.37 (0.049) |
| ≥25kg/m2 | 81 | 7.62 | −0.88 (0.063) | 86 | 7.65 | −0.38 (0.081) |
| Age (years) | ||||||
| <65 | 120 | 7.67 | −0.93 (0.054) | 140 | 7.67 | −0.36 (0.054) |
| ≥65 | 68 | 7.31 | −0.91 (0.066) | 52 | 7.46 | −0.42 (0.080) |
| Gender | ||||||
| Male | 121 | 7.55 | −0.98 (0.051) | 130 | 7.67 | −0.41 (0.060) |
| Female | 67 | 7.53 | −0.81 (0.072) | 62 | 7.51 | −0.30 (0.062) |
| FPG at baseline (mmol/l) | ||||||
| <8.9 (160 mg/dl) | 103 | 7.10 | −0.82 (0.052) | 98 | 7.11 | −0.44 (0.046) |
| ≥8.9 | 85 | 8.08 | −1.05 (0.066) | 94 | 8.14 | −0.31 (0.078) |
| GFR MDRD at baseline [(ml/min)/(1.73 m2)] | ||||||
| Normal >80 | 170 | 7.57 | −0.92 (0.045) | 179 | 7.61 | −0.36 (0.047) |
| Mild >50 to ≤80 | 18 | 7.27 | −0.92 (0.090) | 13 | 7.67 | −0.48 (0.174) |
| 2-h PPG level at baseline (mmol/l) | ||||||
| <12.2 (220 mg/dl) | 64 | 6.94 | −0.75 (0.055) | 61 | 7.04 | −0.40 (0.060) |
| ≥12.2 | 123 | 7.86 | −1.02 (0.055) | 131 | 7.88 | −0.36 (0.060) |
| No data | 1 | 6.60 | 0.00 | |||
BMI, body mass index; FPG, fasting plasma glucose; GFR, glomerular filtration rate; MDRD, modification of diet in renal disease; PPG, postprandial glucose.
*
n is the number of subjects with observations at both baseline and endpoint.